Hoyng P F, Rulo A, Greve E, Watson P, Alm A
Department of Experimental Ophthalmology, Netherlands Ophthalmic Research Institute, Amsterdam, The Netherlands.
Surv Ophthalmol. 1997 Feb;41 Suppl 2:S93-8. doi: 10.1016/s0039-6257(97)80014-8.
Latanoprost, a prostaglandin F2 alpha analogue prodrug, has been shown to be an effective ocular hypotensive agent when used alone on ocular hypertensive or open angle glaucoma patients. In various studies, the ocular hypotensive effects of latanoprost have also been evaluated when used in addition to, or in combination with, other ocular hypotensive agents. Latanoprost produces an additional reduction of intraocular pressure (IOP) when used in combination with timolol, pilocarpine, acetazolamide and dipivefrin. These represent four different classes of glaucoma drugs-beta-adrenergic antagonists, cholinergic agonists, carbonic anhydrase inhibitors, and adrenergic agonists-all of which reduce the IOP by different mechanisms (reduction of aqueous humor production, increased outflow facility, or by a mixed effect on aqueous humor dynamics). All the available evidence shows that latanoprost produces a clinically significant additive ocular hypotensive effect when used in combination with any currently available ocular hypotensive agent.
拉坦前列素是一种前列腺素F2α类似物前药，已证明单独用于高眼压或开角型青光眼患者时，它是一种有效的降眼压药物。在各种研究中，还评估了拉坦前列素与其他降眼压药物联合使用或并用时的降眼压效果。拉坦前列素与噻吗洛尔、毛果芸香碱、乙酰唑胺和地匹福林联合使用时，可进一步降低眼压（IOP）。这些代表了四类不同的青光眼药物——β-肾上腺素能拮抗剂、胆碱能激动剂、碳酸酐酶抑制剂和肾上腺素能激动剂——所有这些药物都通过不同机制降低眼压（减少房水生成、增加房水流出或对房水动力学产生混合作用）。所有现有证据表明，拉坦前列素与任何目前可用的降眼压药物联合使用时，都会产生临床上显著的附加降眼压效果。
